Therapeutic efficacy of an oral nucleoside analog of remdesivir against SARS-CoV-2 pathogenesis in mice.

The COVID-19 pandemic remains uncontrolled despite the rapid rollout of safe and effective SARS-CoV-2 vaccines, underscoring the need to develop highly effective antivirals. In the setting of waning immunity from infection and vaccination, breakthrough infections are becoming increasingly common and...

Descripción completa

Detalles Bibliográficos
Autores principales: Schäfer, Alexandra, Martinez, David R., Won, John J., Moreira, Fernando R., Brown, Ariane J., Gully, Kendra L., Kalla, Rao, Chun, Kwon, Du Pont, Venice, Babusis, Darius, Tang, Jennifer, Murakami, Eisuke, Subramanian, Raju, Barrett, Kimberly T, Bleier, Blake J., Bannister, Roy, Feng, Joy Y., Bilello, John P., Cihlar, Tomas, Mackman, Richard L., Montgomery, Stephanie A., Baric, Ralph S., Sheahan, Timothy P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452096/
https://www.ncbi.nlm.nih.gov/pubmed/34545367
http://dx.doi.org/10.1101/2021.09.13.460111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452096/
https://www.ncbi.nlm.nih.gov/pubmed/34545367
http://dx.doi.org/10.1101/2021.09.13.460111

Ejemplares similares